Industry & Commercialisation | Australian Cardiovascular Alliance (ACvA)
The newly formed ACvA Industry and Commercialisation Committee, is headed by Professor Kerry-Anne Rye and Ben Wright. Call for expressions of interest have been sent to all financial members of the ACvA, to join the Advisory Group for Industry and Commercialisation.
Click HERE to read the position description for Advisory Group Members before applying. Applications close 18 September 2019.
Professor Kerry-Anne Rye
Prof. Kerry Anne Rye, BSc (Hons), PhD, FAHA brings three decades of Australian-based experience in basic scientific discovery, extensive involvement in preclinical testing of drugs involved in cardiovascular clinical outcome trials and, most recently, the development of bi-functional therapies for cardiometabolic disease. Prof. Rye also holds extensive leadership experience at a national and international level. Her National Activities have involved: • Research training of the next generation of CV researchers • SPHERE CV Clinical Academic Group: A collaborative effort between UNSW and affiliated MRIs, The George Institute for Global Health, Liverpool Hospital, Prince of Wales Hospital, Campbelltown Hospital, St George and Sutherland Hospitals, SESLHD, University of Technology Sydney and Western Sydney University. Prof. Rye is the co-lead for the Mechanisms and Causes of Disease theme of the program, the overarching goal of which is to reduce CV disease burden in the community. Prof. Rye’s International Activities include: American Heart Association (AHA) involvement. Vice-Chair (2012-2014) and Chair (2015-2018) of the American Heart Association Scientific Sessions Program Committee for the Arteriosclerosis Thrombosis and Vascular Biology (ATVB) Council. Prof. Rye was instrumental in ensuring that the Australian CV research community was well represented on the faculty of AHA Annual Scientific Sessions. Mentoring: In 2010 Prof. Rye developed and launched the first ever Council-based mentoring program for the AHA. This program was hugely successful, was subsequently adopted by other AHA Councils, and was rolled out in an online format across the entire AHA in 2017. Leadership qualities: Selected previous and current leadership roles and responsibilities are listed below: Academic leadership roles: 2013-2015: Acting Director, Centre for Vascular Research, UNSW. 2015-2016: Head, Mechanisms of Disease and Translational Research, School of Medical Sciences, Faculty of Medicine, UNSW. 2016-Present: Deputy Head and Member of the Executive, School of Medical Sciences, Faculty of Medicine, UNSW Chair of the School of Medical Sciences Animal Advisory Committee Chair of the School of Medical Sciences Heads of Research Committee Member of the Faculty of Medicine Higher Degree Research Committee Member of the Faculty of Medicine Board Member of the Faculty of Medicine Research Committee
Ben is passionate about commercialising emerging technologies, empowering entrepreneurs and building businesses. As a mission focused executive he has driven change for the past 19 years, He loves to champion brilliant people and ideas that address real world needs and solve problems. He has built a career on managed and curated risk, guiding emerging medical technology businesses through Research and Development, Clinical Trials, Operations, and Financial Management across both private and ASX listed companies. Ben is currently the Chief Innovation Officer and Head of Investment Strategy at Cicada Innovations, Australia’s largest deep technology incubator. CHIEF INNOVATION OFFICER / HEAD OF INVESTMENT | CICADA May 2011 – Present As Chief Innovation Officer, his role has involved the sourcing, selecting, mentoring and management of founders and their deep technology startups. Ben has been involved in the creation, execution and mentoring of numerous Accelerator programs and government tenders including the NSW Medical Device Commercialisation Training Program. He enjoys forging deep relationships with founders, helping them develop as entrepreneurs and build great companies. Since 2015, Cicada Innovations companies have raised over $130 M in public and private capital. Ben is a frequent guest lecturer and speaker on Innovation and Entrepreneurship. Cicada Innovations was awarded the accolade of NBIA International Incubator of the Year 2014 and again in 2018. It has also been recognised as Asia Pacific’s leading University associated incubator by UBI Index and is ranked in the top 5 globally. Stanford Graduate School of Business, 2017 Negotiation and Influence, Haas School of Business, UC Berkeley, 2016 Strategy in Competitive Markets, Haas School of Business, UC Berkeley, 2015 Venture Capital, Haas School of Business, UC Berkeley, 2014 Grad. Dip. Biomedical Engineering University of New South Wales, 2003 – 2004 B.Science, Biological Sciences University of Western Sydney, 1997 – 1999